Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

InVivo Therapeutics Slashes 39 Percent of Jobs and Cuts Two R&D Programs in Restructuring

Despite a temporary halt of an experimental spinal cord implant trial following a patient death, InVivo Therapeutics is doubling down and focusing its financial resources on the treatment by initiating a strategic restructuring that includes cutting nearly 40 percent of its workforce.

Read More »

Acorda Plunges After the FDA Rejects Marketing App for Parkinson’s Disease Drug

The U.S. FDA turned down Acorda Therapeutics’ New Drug Application for Inbrija, which was being evaluated for OFF periods in Parkinson’s disease.

Read More »

AstraZeneca, Takeda strike Parkinson’s drug deal

AstraZeneca is to receive up to $400 million from Takeda after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson’s disease.

Read More »

PACIFIC Communications Hires Kent Sewell as Associate Creative Director/Copy

PACIFIC Communications, the West Coast’s largest healthcare communications agency, announced the return of Associate Creative Director/Copy Kent Sewell.

Read More »

Merck cholesterol drug cuts heart risk only 9 percent, future unclear

A large study of a new type of cholesterol medicine from Merck & Co. Inc. found it cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue, leaving its commercial future uncertain.

Read More »

Nandini Ramani Joins Outcome Health as Chief Engineering Officer

Outcome Health, which provides health intelligence in moments of care to improve patient outcomes, announced the hiring of its first Chief Engineering Officer, Nandini Ramani.

Read More »

Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers

Bristol-Myers Squibb Co. and Daiichi Sankyo said they were evaluating a combination of Bristol-Myers’ immuno-oncology drug, Opdivo with the Japanese company’s experimental drug in patients with breast and bladder cancers.

Read More »

FDA steps up scrutiny of stem cell therapies

The U.S. FDA is stepping up efforts to better regulate an emerging field of medicine that holds significant promise for curing some of the most troubling diseases by using the body’s own cells.

Read More »

AstraZeneca taps AI for drug discovery deal

AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.

Read More »

Gilead Sciences to buy Kite Pharma

Gilead Sciences agreed to buy Kite Pharma in a nearly $12 billion deal as it looks to replace flagging sales from hepatitis C drugs via cancer immunotherapies.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!


Ad Right Bottom